| Prev Close | 165.97 |
| Open | 165.57 |
| Day Low/High | 162.28 / 165.78 |
| 52 Wk Low/High | 63.48 / 95.55 |
| Volume | 447.10K |
| Avg Volume | 607.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 88.12M |
| Market Cap | 14.75B |
| EPS | 2.50 |
| P/E Ratio | 61.98 |
| Div & Yield | N.A. (N.A) |
Latest News
A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)
Growth stock are taking a breather, says Jim Cramer. So here's your game plan for next week.
Analysts' Actions -- Box, Caesar's, Goodyear, Idexx Labs and More
Here are Thursday's top research calls, including upgrades for Box and Goodyear, and new coverage of Caesar's Entertainment and Idexx Labs.
Endo Pops After Parkinson's Tests, IDexx Continues Fall, Biogen Higher: Tuesday's Biotech Movers
Biogen's new spine disease drug outperformed expectations during its commercial debut.
Here's Why You Should Hope for Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
These 'Rocket Stocks' Look Ready for Blastoff
These four stocks are showing short-term gain catalysts and longer-term growth potential.
These 4 'Rocket Stocks' Look Ready for Blastoff
These four stocks are showing short-term gain catalysts and longer-term growth potential.
Apple's Streaming Aspirations Not Enough to Get by Facebook: Challenge Update
Here are the highlights from the final round of our Market Bracket Challenge tournament.
Apple Walks All Over Nike, Facebook and Illumina Square Off: Challenge Update
Here are the highlights from the fifth round of our tournament, which will end with an epic tech clash between Apple and Facebook.
Snap's Cinderella Story Continues to Unfold as Nike Squeaks By AT&T: An Update From the Challenge
It has been a wild ride through two rounds of action.
Snap Pulls Off Miracle, Can the Good Times Continue? An Update From the Challenge
It has been a wild ride thus far, and we've only completed one round of action.
Here's a Look at the 64 Best Performing Stocks Over the Last 4 Months
The top 64 companies taking a trip to TheStreet's 2017 Market Bracket Challenge tournament.
Idexx Laboratories: Why I'm Avoiding This Puppy
Households now spend more on their pets than cable TV.
Bonds Call the Tune Today, Not Stocks: Cramer's 'Mad Money' Recap (Thursday 2/9/17)
When bond yields rise, the economy roars and it's game on for industrials, banks and retailers, says Jim Cramer.
Cramer: Reward vs. Political Risk
Trump has made it harder to decide how much volatility you can stand.
Jim Cramer -- Idexx Labs Isn't Done Rallying
Idexx Laboratories beat on earnings per share and revenue expectations, but the trend is still good, Cramer said.
Amazon, Merck, Freshpet: Jim Cramer's Views
Cramer shares his views on the pajama traders, and talks turkey about pet stocks.
Jim Cramer's Top Takeaways: VCA, Johnson Controls, Adient
Cramer can't understand why shares of Johnson Controls spinoff Adient aren't trading higher.
These Stocks Are Too Hot, in a Bad Way : Jim Cramer's 'Mad Money' Recap
Going into earnings what the market needs now is more negativity, Cramer says.
Cramer: Barking Up the Right Tree With Pet Health Stocks
The Mars-VCA deal is yet another sign that pet health is a robust business.
Mars Makes 'Breakthrough Deal' With VCA Acquisition: More Squawk From Jim Cramer
Mars is making moves in 'one of the fastest growing secular stories in the world' with its acquisition of VCA, TheStreet's Jim Cramer said.
Jim Cramer on the Mars Deal for VCA
Jim Cramer says the deal between Mars and VCA is another example of how pet pampering is becoming big business.
